Singapore, Oct. 13 -- Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product:CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.

Activin-A is increasingly recognised as a potential therapeutic agent for conditions such as brain injury and inflammatory diseases. Studies have shown that it can help reduce damage and inflammation, making it a vital tool for researchers exploring new treatments and breakthroughs in these critical areas.

With itsCHO cell-derived purity and reliability, ProSpecBio's Activin-A recombinant protein provides laboratories and academic institutions with t...